11 results about "Antibody expression" patented technology

This invention provides an anti-CD16 antibody, the amino acid sequence of which is selected from SEQ ID NO. 1-3 in the heavy chain CDR region and from SEQ ID NO. 4-6 in the light chain CDR region. This invention belongs to the field of antibodies. It provides a protein sequence of an anti-human CD16 mouse monoclonal antibody, and designs a gene expression base sequence based on the sequenced protein sequence. A stable CHO cell line for recombinant expression of this gene is established. The purified antibody can specifically recognize the human CD16 antigen, and the antibody expression yield is much higher than that of antibodies prepared using traditional hybridoma cells. Furthermore, by replacing mouse IgG1 with rabbit IgG while retaining the variable region, a stable CHO cell line for recombinant expression of the rabbit monoclonal antibody is established. The purified antibody maintains its specific recognition of the human CD16 antigen.

The application belongs to the technical field of biological medicine, and particularly relates to an anti-FOLR1 nanobody and a preparation method and application thereof. The anti-FOLR1 nanobody comprises a framework region and a complementarity determining region, and the complementarity determining region amino acid comprises CDR1, CDR2 and CDR3. The application adopts automatic panning and a mammalian expression system, significantly improves the screening efficiency and antibody expression quality, greatly shortens the development cycle, and provides an efficient tool for FOLR1 targeted diagnosis and treatment. The obtained anti-FOLR1 nanobody exhibits excellent specific recognition and binding capacity.

The present application belongs to the technical field of genetic engineering, and provides an autophagy regulation gene for improving recombinant antibody expression of CHO cells and a cell line construction method and application thereof, wherein the vector for improving recombinant protein expression of CHO cells is any one of a Gadd45b expression vector, a Cdk6 expression vector, a Rrn3 expression vector and a Sirt1 expression vector. The above autophagy-related gene overexpression vector constructed by the present application can realize efficient expression of a transgene in CHO cells when being co-transfected into CHO cells alone or in a certain ratio, and can also improve the expression amount of a recombinant protein when being applied to construction of a CHO cell expression system, thereby helping to break through the bottleneck of low recombinant protein expression level of CHO cells and providing a theoretical basis for recombinant protein production.

This invention provides a peptide-human serum albumin (HSA) conjugate drug, its preparation method, and its application. The peptide-human serum albumin conjugate drug comprises a target tumor cell membrane protein peptide, human serum albumin, and a cytotoxin. This invention innovatively introduces an HSA and covalently conjugates the target tumor cell membrane protein peptide and cytotoxin to the HSA, resulting in a conjugate drug with good stability and minimal cytotoxin loss. This peptide-human serum albumin conjugate drug overcomes the technical shortcomings of large molecular weight and cumbersome preparation of ADCs and insufficient drug loading of traditional PDCs, achieving multiple technical advantages such as high drug loading, small molecular weight, and easy preparation, demonstrating significant advantages and promising application prospects. The preparation method provided by this invention is simple and easy to implement, requiring no complex antibody expression and purification processes, resulting in lower production costs.

The present disclosure is directed to methods for treating a neuropsychiatric disorder associated with expression of autoantibodies to ionotropic glutamate receptor, NMD A 2A (GiuN2A), expression of anti-double-stranded (ds) DNA antibodies that cross react with one or more subunits of the NMD A receptor, or a mutation in the ionotropic glutamate receptor NMD A type subunit 2A (GRIN2A) gene. The methods involve administering a memantine, or a pharmaceutically acceptable salt thereof, to a subject suffering from a neuropsychiatric disorder associated with expression of GluN2A or a mutation in the GRIN2A gene.

The application relates to the technical field of biological medicine, and particularly discloses a monoclonal antibody combined with human CD4 and a preparation method and application thereof. The antibody is obtained by combining single B cell sorting, gene cloning and mammalian cell expression technology after rabbit immunization of a CD4 polypeptide antigen. The antibody has high affinity and good specificity, and can effectively recognize CD4 positive T cells in human peripheral blood. The antibody is verified by ELISA and flow cytometry, and has high titer, low background and a signal-to-noise ratio superior to that of existing mouse-derived antibodies. Further, the amino acid sequences of the light chain and the heavy chain variable region of the antibody are obtained, so that controllability and repeatability of antibody expression are realized. The antibody can be widely applied to scenes such as immunodetection, HIV auxiliary diagnosis, T cell subgroup research and antibody engineering development, and has important scientific research and industrial values.

The present invention relates to an in vitro method for cultivating one or more antibody expressing cell(s). The method comprises cultivating one or more antibody expressing cell(s) obtained from peripheral blood in the presence of IL-2, IL-21 and a non-cell surface presented CD40-stimulating agent and in the absence of feeder cells. Moreover, herein provided are methods for producing antibodies comprising the step of cultivating one or more antibody expressing cell(s) according to the method of the invention, a novel CD40-stimulating agent and uses therefrom as well as a cell culture medium.

The present invention is directed to cationic polymer delivery systems for DNA-mediated antibody expression. The present invention provides cationic polymers electrostatically complexed with gene-encoding nucleic acids including DNA, pDNA, ncDNA, npDNA, and mRNA for delivery to cells to induce the production of antibodies from the polymer polynucleotide complex in vivo. The present invention further relates to a polymer pDNA complex that includes a backbone, any associated pendant groups, ions, or salts thereof. The present invention also provides pharmaceutical compositions, the use of the pharmaceutical compositions as well as kits.

This invention relates to the field of biomedical technology, specifically disclosing a recombinant rabbit monoclonal antibody against human CD3, its preparation method, and its applications. This antibody, obtained by immunizing rabbits to elicit an anti-CD3 immune response, is derived through single-cell B-cell sorting, gene cloning, and a mammalian cell expression system, exhibiting high affinity and good specificity. The antibody can effectively recognize CD3-positive T cells in human peripheral blood and can be applied in flow cytometry, immunohistochemistry, and T cell function studies. Experimental results show that this antibody has advantages such as high titer, strong fluorescence signal, and low background, outperforming traditional murine anti-CD3 antibodies. Further, the amino acid sequences of the variable regions of the light and heavy chains of this antibody were obtained, enabling controllable and reproducible antibody expression. This antibody has significant scientific research value and promising industrial applications, suitable for various scenarios such as T cell marker detection, immune status assessment, and adjuvant research in immunotherapy.